AMICUS THERAPEUTICS, INC. — Director's Dealing 2021

Jan 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-01-15

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-15	Common Stock	A	80327	—	Acquired	940996	Direct
2021-01-15	Common Stock	F	31608	$21.835	Disposed	909388	Direct
2021-01-15	Common Stock	M	22000	$6.45	Acquired	931388	Direct
2021-01-15	Common Stock	S	22000	$22.244	Disposed	909388	Direct
2021-01-20	Common Stock	S	50000	$21.5065	Disposed	859388	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-15	Stock Options (right to buy)	$6.45	M	22000	Disposed	2022-02-15	Common Stock (22000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: Granted for the achievement of the 2018 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $21.82 to $22.86 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All of these options were fully vested and exercisable as of January 15, 2021.